ReviewImmunologic research2013
Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab.
Review in Immunologic research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 43 citations in OpenAlex.
- Emerging Treatments in Pemphigus: Is Healing an Achievable Goal?American journal of clinical dermatology · 2026Review
- Pemphigus Vulgaris Unmasked in a Patient With Behçet's Disease: A Complex Diagnostic Dilemma.Cureus · 2024Article
- [Pemphigus: current and future treatment strategies].Dermatologie (Heidelberg, Germany) · 2022Review
- Informed consent and biological agents in rheumatology and internal medicine.European journal of clinical investigation · 2022Review
- Immunotherapy for Pemphigus: Present and Future.Frontiers in medicine · 2022Review
- Clinical Manifestations and Management of Pediatric Behçet's Disease.Clinical reviews in allergy & immunology · 2021Review
- Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.BMC pediatrics · 2019Article
- From autoinflammation to autoimmunity: old and recent findings.Clinical rheumatology · 2018Review
- Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.Rheumatology international · 2018Review
- IL-6 blockade in the management of non-infectious uveitis.Clinical rheumatology · 2017Review
- The continuing evolution of targeted therapy for inflammatory skin disease.Seminars in immunopathology · 2016Review
- Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab.Clinical rheumatology · 2015Article
- Efficacy of tocilizumab in a patient with refractory psoriatic arthritis.Clinical rheumatology · 2014Article
- Biological treatments in Behçet's disease: beyond anti-TNF therapy.Mediators of inflammation · 2014Review
- Unraveling the soul of autoimmune diseases: pathogenesis, diagnosis and treatment adding dowels to the puzzle.Immunologic research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pemphigus foliaceus (PF) and Behçet's disease (BD) are immune-mediated conditions which are usually treated with corticosteroids, immunosuppressants, and, when refractory, with biologic agents. In both diseases, interleukin (IL)-6 serum levels are increased driving the immune-mediated inflammatory process. Tocilizumab is a humanized monoclonal antibody, targeting IL6-receptor, used in the treatment of rheumatoid arthritis. Besides the current indication, it has been recently administered to patients with refractory immune inflammatory diseases as an off-label treatment. Here, we report the case of a woman affected with PF and BD, who did not respond to corticosteroids, immunosuppressants, and biologic agents including adalimumab, anakinra, and infliximab. A complete, long-lasting, clinical, and serological remission was achieved only with tocilizumab. To the best of our knowledge, the association between PF and BD has never been reported. Moreover, only two cases of BD and no cases of PF treated with tocilizumab have been described to date. A literature review on the use of biologic agents on patients with PF and BD was also carried out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.